（文章来源：每日经济新闻） 每经AI快讯，12月16日，辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

格隆汇12月16日｜辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

本文源自：金融界AI电报 辉瑞(PFE.N)股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 来源：滚动播报 ...

周二，辉瑞(PFE.US)跌逾4%，报25.27美元。消息面上，辉瑞预测，随着该公司正努力通过一系列昂贵 的收购来更新其热门药物产品线，明年的销售增长将微乎其微甚至没有增长。辉瑞公司周二在一份声明 中表示，预计2026年营收将在595亿美元至625亿美元之间，与华尔街的预期大致相符。今年销售额预计 为620亿美元，与该公司11月初的指引范围一致。该公司预计明年调整后每股收益将位于2.80美元至3美 元之间。 首席执行官Albert Bourla正面临着重振辉瑞的关键时刻，因为几年前推动公司销售额激增的新冠疫苗和 治疗药物的需求正在消退新冠相关产品的收入仍在下降；辉瑞预测，明年这些产品的销售额将减少约15 亿美元至50亿美元。 ...

首席执行官Albert Bourla正面临着重振辉瑞的关键时刻，因为几年前推动公司销售额激增的新冠疫苗和 治疗药物的需求正在消退新冠相关产品的收入仍在下降；辉瑞预测，明年这些产品的销售额将减少约15 亿美元至50亿美元。 智通财经APP获悉，周二，辉瑞(PFE.US)跌逾4%，报25.27美元。 消息面上，辉瑞预测，随着该公司正 努力通过一系列昂贵的收购来更新其热门药物产品线，明年的销售增长将微乎其微甚至没有增长。辉瑞 公司周二在一份声明中表示，预计2026年营收将在595亿美元至625亿美元之间，与华尔街的预期大致相 符。今年销售额预计为620亿美元，与该公司11月初的指引范围一致。该公司预计明年调整后每股收益 将位于2.80美元至3美元之间。 ...

专题：聚焦2025年第三季度美股财报 核心要点 2025 年 10 月 16 日，美国加利福尼亚州南旧金山市，一栋玻璃幕墙办公大楼外墙上的辉瑞标识，与天空倒影相映 成景。 辉瑞于本周二发布 2026 年业绩指引，整体基调趋于保守。面对新冠相关产品销售额下滑及老药收入缩 水的双重压力，公司计划通过对管线资产进行长期投资来扭转局面。 对于辉瑞而言，上述挑战既非突发状况，也算不上新问题。疫情期间，辉瑞凭借新冠疫苗与抗病毒药物 斩获创纪录营收，但此后相关产品销售额便大幅下滑。为打造新的收入来源，辉瑞近年来频频出手，达 成多笔规模不一的并购交易，例如近期刚刚完成的、以 100 亿美元收购肥胖症生物科技公司梅瑟拉的交 易，以及 2023 年斥资 430 亿美元收购抗癌药企西格玛的重磅并购案。 然而，本次业绩指引清晰地表明，这些投资项目距离产生回报仍有较长的路要走。以梅瑟拉为例，其旗 下管线药物目前仍处于早期研发阶段。 在周二交易中，辉瑞股价基本持平。该公司股价今年以来整体也未出现明显波动。 辉瑞预计，2026 年调整后每股收益区间为 2.80-3.00 美元。根据路孚特的数据，这一数值略低于分析师 普遍预期的 3.05 ...

Core Viewpoint - Pfizer is forecasting modest guidance for 2026 as it focuses on long-term investments in its pipeline to mitigate declining sales from Covid products and older drugs [1] Group 1: Financial Outlook - Pfizer expects adjusted profit for 2026 to be between $2.80 and $3 per share, slightly below analysts' consensus estimate of $3.05 per share [3] - Revenue is projected to be between $59.5 billion and $62.5 billion, which is largely flat compared to the 2025 sales guidance of $62 billion [4] - The company anticipates a decline of approximately $1.5 billion in sales from Covid vaccine and antiviral pill Paxlovid, projecting 2026 sales from these products to be around $5 billion [4] Group 2: Market Challenges - Pfizer is facing a projected $1.5 billion year-over-year drop in sales due to certain products losing market exclusivity, with increased competition impacting blockbuster drugs like Prevnar [5] - Patent expirations are expected to significantly affect revenues, with an estimated $17 billion impacted by expirations occurring primarily in 2026 and 2028 [6] Group 3: Strategic Investments - The company has made significant acquisitions, including a $10 billion deal for Metsera and a $43 billion acquisition of Seagen, to build new revenue streams [2] - However, the benefits from these investments are still distant, as Metsera's pipeline consists of drugs in early-stage development [3] Group 4: Cost Management - Pfizer has exceeded its cost-saving goals for 2025 and is targeting over $7 billion in cost cuts by 2027, expecting to deliver most of these savings by next year [8] - The guidance reflects costs associated with recent acquisitions, including Metsera [7] Group 5: Regulatory Environment - The company is navigating changes in U.S. vaccine policy, which has introduced uncertainty, particularly under Health and Human Services Secretary Robert F. Kennedy Jr. [9] - Pfizer's CEO stated that comments from the FDA regarding vaccines do not merit concern and will not alter the company's long-term investment strategy [10] Group 6: Pricing Strategy - Pfizer has entered a drug pricing deal that includes selling existing drugs to Medicaid patients at the lowest price offered in other developed nations, which will lead to price and margin compression in 2026 [11]

本文源自：金融界AI电报 辉瑞(PFE.N)股价转跌，跌幅扩大至3%。 ...

辉瑞(PFE.US)跌超3%，报25.62美元。消息面上，辉瑞确认2025财年调整后每股收益指引为3至3.15美 元，市场预期为3.14美元；销售额指引从610亿至640亿美元收窄至约620亿美元，市场预期为624.75亿美 元。公司预计2026财年营收将在595亿至625亿美元之间，大致符合预期。(格隆汇) ...